3.52  0.78 (28.47%)		03-09 16:00
Open: 2.72 High: 3.788 Volume: 765,223		Pre. Close: 2.74 Low: 2.6401 Market Cap: 166(M)

Short term
Mid term
Targets	6-month :	36.28	1-year :	57.12
Resists	First :	31.06	Second :	48.9
Pivot price	2.91
Supports	First :	2.2	Second :	1.83
MAs	MA(5) :	2.89	MA(20) :	3.15
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	25.8	D(3) :	20.4
RSI	RSI(14): 19.5
52-week	High :	33.9	Low :	2.2

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PLYX ] has closed below upper band by 9.6%. Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	2.86 - 2.88	2.88 - 2.89
Low:	2.54 - 2.56	2.56 - 2.58
Close:	2.7 - 2.74	2.74 - 2.77

Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Its pipeline includes PLX-100, a combination of PLX-200 and a supplement for late infantile neuronal ceroid lipofuscinosis (LINCL) and other forms of NCL; PLX-200, a repurposed drug that is used to treat other diseases in adults and children; and PLX-300, a drug isolated from an edible plant that activates PPARa, which enhances production of transcription factor EB. The company was founded in 2014 and is based in Paramus, New Jersey.

Mon, 02 Feb 2026
Polaryx Therapeutics, Clinical-Stage Developer of Therapies for Lysosomal Storage Disorders, Files for Nasdaq Capital Market IPO - TradingView

Mon, 02 Feb 2026
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX” - marketscreener.com

Mon, 02 Feb 2026
Mstone Portfolio Company, Polaryx Therapeutics, Announces Direct Listing on Nasdaq - The Progress Index

Fri, 30 Jan 2026
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq - The Manila Times

Fri, 30 Jan 2026
Biotech targeting rare pediatric diseases heads to Nasdaq Feb. 2 - Stock Titan

Wed, 26 Nov 2025
PLYX Stock Price and Chart — NASDAQ:PLYX - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	1 (M)
Held by Insiders	52.7 (%)
Held by Institutions	0 (%)
Shares Short	26 (K)
Shares Short P.Month	0 (K)

EPS	-0.18
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.1
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-20.71
PEG Ratio	0
Price to Book value	32
Price to Sales	0
Price to Cash Flow	-0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.